DVAX
Price
$10.84
Change
+$0.05 (+0.46%)
Updated
Aug 18, 03:16 PM (EDT)
Capitalization
1.27B
73 days until earnings call
LNTH
Price
$55.70
Change
+$1.52 (+2.81%)
Updated
Aug 18, 03:41 PM (EDT)
Capitalization
3.68B
73 days until earnings call
Interact to see
Advertisement

DVAX vs LNTH

Header iconDVAX vs LNTH Comparison
Open Charts DVAX vs LNTHBanner chart's image
Dynavax Technologies
Price$10.84
Change+$0.05 (+0.46%)
Volume$100
Capitalization1.27B
Lantheus Holdings
Price$55.70
Change+$1.52 (+2.81%)
Volume$10.31K
Capitalization3.68B
DVAX vs LNTH Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. LNTH commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and LNTH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (DVAX: $10.79 vs. LNTH: $54.18)
Brand notoriety: DVAX and LNTH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 64% vs. LNTH: 81%
Market capitalization -- DVAX: $1.27B vs. LNTH: $3.68B
DVAX [@Pharmaceuticals: Generic] is valued at $1.27B. LNTH’s [@Pharmaceuticals: Generic] market capitalization is $3.68B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileLNTH’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • LNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, LNTH is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 5 TA indicator(s) are bullish while LNTH’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 5 bullish, 4 bearish.
  • LNTH’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than LNTH.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а +4.45% price change this week, while LNTH (@Pharmaceuticals: Generic) price change was -5.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.59%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +76.92%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

LNTH is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.59% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LNTH($3.68B) has a higher market cap than DVAX($1.27B). DVAX has higher P/E ratio than LNTH: DVAX (54.60) vs LNTH (14.41). DVAX YTD gains are higher at: -15.505 vs. LNTH (-39.437). LNTH has higher annual earnings (EBITDA): 439M vs. DVAX (-40.59M). LNTH has more cash in the bank: 939M vs. DVAX (661M). DVAX has less debt than LNTH: DVAX (286M) vs LNTH (614M). LNTH has higher revenues than DVAX: LNTH (1.54B) vs DVAX (295M).
DVAXLNTHDVAX / LNTH
Capitalization1.27B3.68B34%
EBITDA-40.59M439M-9%
Gain YTD-15.505-39.43739%
P/E Ratio54.6014.41379%
Revenue295M1.54B19%
Total Cash661M939M70%
Total Debt286M614M47%
FUNDAMENTALS RATINGS
DVAX vs LNTH: Fundamental Ratings
DVAX
LNTH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
9440
PRICE GROWTH RATING
1..100
5792
P/E GROWTH RATING
1..100
9762
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LNTH's Valuation (60) in the Medical Specialties industry is in the same range as DVAX (72) in the Biotechnology industry. This means that LNTH’s stock grew similarly to DVAX’s over the last 12 months.

LNTH's Profit vs Risk Rating (62) in the Medical Specialties industry is somewhat better than the same rating for DVAX (100) in the Biotechnology industry. This means that LNTH’s stock grew somewhat faster than DVAX’s over the last 12 months.

LNTH's SMR Rating (40) in the Medical Specialties industry is somewhat better than the same rating for DVAX (94) in the Biotechnology industry. This means that LNTH’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for LNTH (92) in the Medical Specialties industry. This means that DVAX’s stock grew somewhat faster than LNTH’s over the last 12 months.

LNTH's P/E Growth Rating (62) in the Medical Specialties industry is somewhat better than the same rating for DVAX (97) in the Biotechnology industry. This means that LNTH’s stock grew somewhat faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXLNTH
RSI
ODDS (%)
Bearish Trend 4 days ago
63%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
74%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
66%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 6 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
87%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGFRX13.71N/A
N/A
William Blair Growth R6
MRCGX29.76-0.01
-0.03%
Meridian Growth C
MNDAX26.42-0.06
-0.23%
MFS New Discovery A
HDCEX10.00-0.03
-0.30%
Rational Equity Armor Fund C
UBVLX85.09-0.82
-0.95%
Undiscovered Managers Behavioral Val L

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ALKS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ALKS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+1.60%
ALKS - DVAX
34%
Loosely correlated
+2.80%
SUPN - DVAX
34%
Loosely correlated
+1.23%
AMRX - DVAX
33%
Loosely correlated
+0.64%
BCRX - DVAX
33%
Poorly correlated
-0.95%
ESPR - DVAX
31%
Poorly correlated
N/A
More

LNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, LNTH has been loosely correlated with EOLS. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if LNTH jumps, then EOLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LNTH
1D Price
Change %
LNTH100%
-0.53%
EOLS - LNTH
33%
Loosely correlated
+5.16%
CRDL - LNTH
29%
Poorly correlated
N/A
MKKGY - LNTH
27%
Poorly correlated
+2.36%
DVAX - LNTH
25%
Poorly correlated
+1.60%
ACB - LNTH
23%
Poorly correlated
-5.75%
More